Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients
- 24 March 2008
- journal article
- research article
- Published by Wiley in Pediatric Pulmonology
- Vol. 43 (5) , 463-471
Abstract
Rationale: Chronic mucoid Pseudomonas aeruginosa within the airway in cystic fibrosis (CF) patients can determine prognosis. Understanding the risk factors of mucoid P. aeruginosa acquisition may change how we deliver care. This study aims to evaluate whether presence of risk factors reported to predict disease severity including gender, CFTR genotype, bacterial organisms in airway cultures, and serum levels of vitamins A and E, albumin, C‐reactive protein, alpha 1‐antitrypsin, and immunoglobulins increased the risk of mucoid P. aeruginosa acquisition.Methods: Primary endpoint was age at first transition from negative to positive culture for mucoid P. aeruginosa. Cox proportional hazards regression with time‐dependent covariates examined development of mucoid P. aeruginosa infection and its association with longitudinally measured serum biomarkers, pulmonary function, and culture results for other organisms.Results: Median ages at CF diagnosis and at first culture were 0.55 and 5.7 years, respectively. Median number of cultures/patient was 17. Of the 323 subjects, 150 developed mucoid P. aeruginosa during a median 8.1 years' follow‐up. In multivariate analysis, gender (relative hazard [RH] 0.55 for male vs. female, P = 0.001), number of DF508 alleles (RH 1.66 for 1 or 2 vs. 0, P = 0.04), FEV1 % (RH 1.16 for 10% decrease, P = 0.008), and most recent Staphylococcus aureus status (RH 0.24 for positive vs. negative, P < 0.0001) remained statistically significant.Conclusion: Female gender, number of DF508 alleles, decreased lung function, and lack of S. aureus on recent sputum culture are important risk factors for early detection of mucoid P. aeruginosa. Pediatr Pulmonol. 2008; 43:463–471.Keywords
This publication has 34 references indexed in Scilit:
- Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosisPediatric Pulmonology, 2007
- Duration of treatment effect after tobramycin solution for inhalation in young children with cystic fibrosisPediatric Pulmonology, 2007
- Inflammatory markers of lung disease in adult patients with cystic fibrosisPediatric Pulmonology, 2007
- Sex Differences in Habitual Physical Activity and Lung Function Decline in Children with Cystic FibrosisThe Journal of Pediatrics, 2005
- Risk factors for initial acquisition of Pseudomonas aeruginosa in children with cystic fibrosis identified by newborn screeningPediatric Pulmonology, 2003
- Longitudinal Assessment ofPseudomonas aeruginosain Young Children with Cystic FibrosisThe Journal of Infectious Diseases, 2001
- Effect of continuous antistaphylococcal therapy on the rate ofP. aeruginosa acquisition in patients with cystic fibrosisPediatric Pulmonology, 2001
- Gender differences in cystic fibrosis: Pseudomonas aeruginosa infectionJournal of Clinical Epidemiology, 1995
- Severity of cystic fibrosis in patients homozygous and heterozygous for ΔF508 mutationThe Lancet, 1991
- Cystic fibrosis. 1. Pseudomonas aeruginosa infection in cystic fibrosis and its management.Thorax, 1990